All Photos(1)
1-(2-methyl-5-nitro-1H-imidazol-1-yl) propan-2ol, 1-(2Hydroxypropyl)-2-methyl-5-nitroimidazole, SYM-1219
C7H11N3O3
Recommended Products
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
InChI
1S/C7H11N3O3/c1-5(11)4-9-6(2)8-3-7(9)10(12)13/h3,5,11H,4H2,1-2H3
InChI key
KPQZUUQMTUIKBP-UHFFFAOYSA-N
Related Categories
Biochem/physiol Actions
Secnidazole is a nitroimidazole anti-microbial selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa. It has been approved for the treatment of bacterial vaginosis. Secnidazole is a prodrug, whose nitro group is reduced by bacterial enzymes to radical anions that interfere with bacterial DNA synthesis.
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Journal of clinical pharmacology, 58(3), 286-293 (2017-10-03)
SYM-1219, a novel oral granule formulation of secnidazole, is under development as single-dose treatment for bacterial vaginosis. This 4-way, randomized, crossover study evaluated the effects of SYM-1219 on electrocardiographic (ECG) parameters in 52 healthy subjects. Subjects were administered single doses
Anaerobe, 47, 115-119 (2017-05-20)
Secnidazole, a 5-nitroimidazole with a longer half-life, is structurally related to metronidazole and tinidazole. For treatment of bacterial vaginosis (BV), secnidazole is a suitable single-dose oral drug having a longer serum half-life than metronidazole. The objective of this study was
Advances in therapy, 33(12), 2229-2241 (2016-10-17)
Bacterial vaginosis (BV) is a serious infection that is the most common vaginal infection in women of childbearing potential. SYM-1219 is a novel, granule formulation containing 2 g of secnidazole that is being developed as a single, oral dose to treat
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service